China Medipharm Insights - Issue 64


Regular Price: USD 1,000.00

Special Price USD 700.00

30% OFF

* Required Fields

Regular Price: USD 1,000.00

Special Price USD 700.00


Be the first to review this product

Table of Contents

China Medipharm Insights - Issue 64, Market AnalysisChinese Pharmaceutical Industry Posts 12.8 Percent Growth in Year 2000Hospital Drug ConsumptionDrug consumptionConsumption of Anti-hypertensives in Fuzhou Hospitals 1997-2000Product NewsSDA Suspends Sales of Lipobay in ChinaAnti-diabetes Pioglitazone Launched by Beijing Taiyang PharmaPaclitaxel Put into Trial Production in FujianPlavix Marketed by Sanofi-Minsheng PharmaMedium and Long Chain Fat Emulsion Marketed by Guangzhou QiaoguangClavulanate K/amoxicillin Compound Granules to Be MarketedClass I Human Recombinant Endostatin Enters Clinical TrialsAnti-cancer Adjuvant Amifostine Put into Production in LiuyangAnti-cancer Ginsenoside Rg3 Project Approved by SDPCInjectable Ethyol Launched by Hunan Yinhe Biochemical EngineeringAnti-cancer TCM Tanepin to Start Phase II Clinical Trials in USAnti-hypertensive Sushi Developed by Haibin Pharma of Shenzhen Taita PharmaXantinol Hydrochloride Sodium Chloride Put into Production in Hualu PharmaCompany ProfilesNorth China Pharma Expands Penicillin ProductionForeign Investment Strengthens North China Pharma Group’s CompetitivenessShiyao Group Marching forwardZhongxin Medicines Aims to Open 500 Chain DrugstoresTianjin Lisheng Pharma EstablishedShanxi Aurobindo Tongling Pharma Booming on CooperationJiangsu Hengrui Medicines Company Expands in ShanghaiShanghai Biochip Company EstablishedJiangsu Wuzhong Focuses on High Tech DrugsSSMU-AAI Center for Drug Research and Clinical Pharmacology EstablishedTianjin Hualong Pharmaceutical Co. EstablishedZhejiang Chengyi Pharma EstablishedBeijing Novartis Holds Organ Transplant SeminarsWeibang Biopharma EstablishedGMP Certification Announcements by SDAMarket Analysis of Osteoporosis Drugs MarketMarket Analysis of Osteoporosis Drugs MarketA Brief Analysis of Ophthalmic Drug MarketProduct AnalysisMarket Analysis of Ginkgo ProductsNews in BriefProfitability of Pharmaceutical Industry Improves in the First Quarter of 2001Shanghai Strengthens Health Insurance SystemChina to Implement Multi-layer Health Insurance SystemHypertension Very Prevalent in the CountryIncidence of Cancer Keeps RisingLeprosy Control Improved in ChinaDrug Makers Rush to Retail Drug MarketDrug ProcurementFujian to Expand Unified Drug Procurement-through-BiddingGuizhou to Conduct First Unified Drug Procurement-through-BiddingDrug Prices Fall in Guangxi Through Unified Drug Procurement-by-BiddingDrug Purchase Price Lowered by 43 Percent in GuangxiYunnan to Kick Off Unified Drug-ProcurementHainan to Use Online Bidding for Big Unified Drug-Procurement ProgramUnified Drug Procurement-through-Bidding in Guangzhou

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.